INTRODUCTION
Alzheimer's disease (AD) is a common cause of mild cognitive impairment (MCI). 1, 2 However, the time from MCI to dementia is highly variable and ranges from less than a year to up to ten years. 2 Subjects with MCI and evidence of underlying AD pathology are now recognized as having prodromal AD 3 or MCI due to AD, 4 but still little is known about clinical progression in these subjects. It is important to identify markers of progression in subjects with MCI who will progress to AD-type dementia to give subjects a prognosis and select subjects for treatment trials in the predementia phase of AD. 5 The aim of the present study was to assess which previously identified biomarkers and risk factors for AD were associated with time from MCI to dementia in subjects who all progressed to AD-type dementia (MCI-AD). We also compared subjects with MCI-AD to subjects with MCI who did not progress to AD-type dementia during follow-up. We selected predictor variables based on the amyloid cascade model. [6] [7] [8] According to this model, the central feature of AD pathology is abnormal amyloid-ß processing. This results from a combination of genetic or acquired risk factors. Abnormal amyloid-ß processing subsequently leads to brain injury, which can be measured by markers for neurodegeneration, brain atrophy and cognitive impairment. We hypothesized that risk factors, amyloid markers and injury markers all could predict whether a subject with MCI had MCI-AD at baseline. We further hypothesized that among subjects with MCI-AD only injury markers would be associated with rapid decline to dementia, because they reflect a more advanced stage of the disease.
MATERIALS AND METHODS

Subjects
We included subjects with MCI, who had their first visit at our memory clinic of the Alzheimer Center of the VU University Medical Center between 1998 and 2007. Inclusion criteria were age > 54 year and availability of CSF and / or MRI within 11 months from baseline. Subjects with obvious causes for MCI other than AD, such as alcohol abuse or severe depression were excluded. Of the 248 subjects who fulfilled these criteria, 203 had at least one follow up visit. Of these 203 subjects, 91 progressed to Alzheimer-type dementia and were considered to have MCI-AD at baseline. The ethical review board of the VUMC approved the study and all subjects gave written informed consent.
neurologists, neuropsychologists, a psychiatrist and a radiologist, all blinded to CSF results and APOE status. MCI was diagnosed based on the results of the clinical and neuropsychological examination, according to Petersen criteria. 19 We included both subjects with amnestic MCI and non-amnestic MCI. For most subjects, follow up visits were part of regular patient care. The follow up visits were performed with an interval from 6 to 12 months and included medical history, neurological examination and cognitive tests. Diagnosis of probable AD was made according to the NINCDS-ADRDA criteria. 20 Time to dementia was defined as the time between baseline visit and the date AD-type dementia was diagnosed.
CSF analysis
CSF was obtained by lumbar puncture between the L3/L4 or L4/L5 intervertebral space, using a 25-gauge needle, and collected in 10 ml polypropylene tubes. Within 2 hours, CSF samples were centrifuged at 1800 x g for 10 minutes at 4°C. A small amount of CSF was used for routine analyses, including total cells (leukocytes and erythrocytes), total protein and glucose. CSF was aliquoted in polypropylene tubes of 0.5 or 1 ml and stored at -80°C until further analysis. CSF amyloid-ß1-42 (Aβ1-42), total tau (t-tau) and tau phosphorylated at threonine 181 (p-tau) were measured with Innotest sandwich ELISA as described previously. 21 Because no internationally accepted reference material is available for these biomarkers, the performance of the assays was monitored with pools of surplus CSF specimens. In the study period, multiple specimens with various concentrations, which were included in 7-18 runs have been used for this purpose. The interassay coefficients of variation were mean ± standard deviation (SD) 11.3±4.9% for Aβ1-42, 9.3±1.5% for tau and 9.4±2.5% for p-tau-181. The team involved in the CSF analysis was not aware of clinical diagnosis. CSF was available of 122 of the 203 MCI subjects (60%) and of 56 of the 91 subjects with MCI-AD (62%). In the subjects with MCI-AD mean±SD time between baseline visit and LP was 2.1±3.2 months.
MRI assessment
MRI scans were made on a 1.0 Tesla scanner (Siemens Magnetom Impact Expert, Erlangen, Germany) and included a coronal T1-weighted 3D inversion-prepared gradient echo sequence (168 slices, FOV 250 mm, matrix 256 x 256; slice thickness 1.5 mm, TE 7 ms, TR 15 ms, TI 300 ms, flip angle 15 degrees). Medial temporal lobe atrophy (MTA) was rated visually according to the method of Scheltens et al, 22 in which the score ranges from 0 (no atrophy) to 4 (severe atrophy), using oblique reconstructions of the MP-RAGE sequences, perpendicular to the long axis of the hippocampus. MTA scores of the left and right hippocampi were averaged. A trained rater, who was blinded to clinical information, rated MTA. MRI-scan was available of 181 of the 203 MCI subjects (89%) and of 78 of the 91 subjects with MCI-AD (86%). In the subjects with MCI-AD mean±SD time between baseline visit and MRI was 1.2±1.8 months.
APOE genotyping
DNA was isolated from 10 ml EDTA blood for Apolipoprotein E (APOE) genotyping, using the light cycler APOE mutation detection kit (Roche Diagnostics GmbH, Mannheim, Germany).
APOE genotype was determined in 153 of the 203 MCI subjects (75%) and in 63 of the 91 subjects with MCI-AD (69%). Subjects were classified as APOE-ε4 positive when having one or two APOE-ε4 alleles.
Statistical analysis
Analyses were performed with SPSS 18.0 for the Macintosh. Group differences at baseline were analysed using chi-squared tests for categorical variables and Student's t-tests for continuous variables. CSF markers were log transformed in order to obtain normal distribution. For the survival analyses we dichotomized age, educational level, levels of CSF markers and the MMSE score with a split-half approach, using the median value as a cut-off point (table 2) . Medial temporal lobe atrophy was defined as a mean MTA score of left and right side of at least 1.5.
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The main analyses on the association of predictors with time to AD-type dementia in subjects with MCI-AD were performed using Kaplan-Meier analysis and log-rank statistics. In addition we performed survival analyses using Cox proportional hazards with correction for age, gender and educational level using the dichotomized values of the respective biomarkers as described above. Of the biomarkers that were associated with rapid progression to dementia we also assessed the association with decline in MMSE score. We performed mixed models analyses with an unstructured co-variance structure with correction for age, gender and educational level. 23 We included MMSE scores at follow up untill conversion to AD type dementia over a 3-year period.
RESULTS
Subject characteristics
We included a total of 203 MCI subjects with at least 1 follow up. Subjects were on average ±SD 71±8 years old and had 11±3 years of education. Ninety subjects were female (44%) and 52% had at least one APOE-ε4 allele. Average MMSE score at baseline was 27±2. Baseline characteristics are shown in table 1. Ninety-one of the 203 subjects (45%) progressed to AD-type dementia and were considered to have MCI-AD at baseline. Mean time to dementia was 2.2±1.3 years, with a range from 5 months till 7 years. Mean MMSE score at the time of AD-type dementia diagnosis was 23.6±3.2. This score was not dependent on biomarker status at baseline (data not shown).
Of the 112 subjects that did not progress to AD-type dementia, 93 (83%) remained stable and 19 (17%) progressed to other types of dementia. Removing these 19 subjects from the analyses did not influence the results.
Markers of MCI-AD in subjects with MCI
Subjects with MCI-AD were older, more frequently female and more frequently carrier of the APOE-ε4 allele than the MCI subjects who did not progress to AD-type dementia during follow up. Subjects with MCI-AD also had lower levels of CSF Aβ1-42, higher levels of CSF t-tau and p-tau, more medial temporal lobe atrophy and lower scores on the MMSE at baseline (table 1) .
Predictors of time to dementia in subjects with MCI-AD
Kaplan-Meier analyses showed that among the 91 subjects with MCI-AD, increased levels of CSF t-tau and p-tau, medial temporal lobe atrophy, and low MMSE scores were associated with rapid progression to dementia ( .007) were associated with rapid decline to dementia. High levels of t-tau (HR 1.7, 95% CI 1.0-3.2, p=0.07) and p-tau (HR 1.7, 95% CI 0.9-2.9, p=0.08) tended to be associated with rapid decline to dementia. The APOE-ε4 allele (HR 0.6, 95% CI 0.4-1.1, p=0.1) and CSF level of Aβ1-42 (HR 0.9, 95% CI 0.5-1.7, p=0.7) were not associated with time to dementia. In order to investigate whether CSF t-tau, MTA, and MMSE score were independently associated with time to dementia, we performed Cox proportional hazards analysis with correction for age in subjects who had data of all biomarkers available (N=37). When all data were entered in a single model with correction for age, MTA score (HR=2.6, 95% CI 1.1-6.1, p=0.03) was associated with time to dementia and CSF t-tau (HR= 2.0, 95% CI 0.9-4.2, p=0.08) tended to be associated with time to dementia. MMSE score was no longer associated with outcome (p=0.8).
MMSE slope analyses in subjects with MCI-AD
We next investigated whether subjects who more rapidly progressed to dementia suffered from a more aggressive course of the disease or were already in a more advanced stage of the + MRI scan was available for 76 subjects with MCI-AD and 103 subjects with MCI-other. *p ≤ 0.05, † p ≤ 0.01, ± p ≤ 0.001 compared to no AD at follow up. § Averaged score of left and right side on a visual rating scale ranging from 0 (no atrophy) to 4 (severe atrophy). Abbreviations: MCI-AD = subjects with mild cognitive impairment at baseline who progressed to AD-type dementia during follow up, CSF = cerebrospinal fluid, Aβ1-42 = amyloid-ß1-42, t-tau = total tau, p-tau = tau phosphorylated at threonine 181, MTA = medial temporal lobe atrophy, MMSE = mini-mental state examination. disease at baseline. As a proxy of the stage of the disease we used the MMSE score at baseline (intercept of the slope) and as a measure for disease course we used the slope of decline in MMSE score. Subjects with high levels of CSF t-tau or p-tau had lower MMSE scores at baseline, but the same slope of decline, compared to subjects with low levels (table 3, figure 2 .A). Compared to subjects without MTA, subjects with MTA had similar baseline MMSE scores, but a more rapid decline in MMSE score (table 3, figure 2 .B). Subjects with a low MMSE score had the same decline in MMSE score compared to subjects with a high MMSE score at baseline (table 3). Kaplan-Meier analyses for time to dementia in subjects with MCI-AD. Cut off points are based on median values for age, education, CSF markers, MTA and MMSE score. * Average of left and right side on a visual rating scale ranging from 0 (no atrophy) to 4 (severe atrophy). Abbreviations: MCI-AD = subjects with mild cognitive impairment at baseline who progressed to AD-type dementia during follow up, CSF = cerebrospinal fluid, Aβ1-42 = amyloid-ß1-42, t-tau = total tau, p-tau = tau phosphorylated at threonine 181, MTA = medial temporal lobe atrophy, MMSE = mini-mental state examination. Figure 1 . Progression to dementia in subjects with MCI-AD according to CSF Aβ1-42 and t-tau, MTA and MMSE status at baseline. Kaplan-Meier survival curves of time to dementia according to CSF Aβ1-42 levels (A, N=56), CSF t-tau levels (B, N=56), medial temporal lobe atrophy (C, N=76) and MMSE score (D, N=91) at baseline. Dotted lines indicate the 50% subjects with more severe pathology, defined as CSF Aβ1-42 ≤ 435 pg/ml (A), CSF tau ≥ 627 pg/ml (B), mean MTA score ≥ 1.5 (C) and MMSE score ≤ 26 (D). Solid black lines indicate the subjects with less severe pathology defined as CSF Aβ1-42 > 435 pg/ml (A), CSF t-tau < 627 pg/ml (B), mean MTA score < 1.5 (C) and MMSE score > 26 (D). P-values refer to group differences for time to dementia assessed with log rank statistics. Abbreviations: MCI-AD = subjects with mild cognitive impairment at baseline who progressed to AD-type dementia during follow up, CSF = cerebrospinal fluid, Aβ1-42 = amyloid-ß1-42, t-tau = total tau, MTA = medial temporal lobe atrophy, MMSE = mini-mental state examination. Decline in MMSE score in subjects with MCI-AD according to CSF t-tau and MTA score at baseline. Slopes of decline in MMSE score in subjects with MCI-AD. Subjects were classified according to CSF t-tau levels (A) and medial temporal lobe atrophy (B) at baseline. Dotted lines indicate the 50% subjects with more severe pathology at baseline, defined as CSF tau ≥ 627 pg/ml (A) and mean MTA score ≥ 1.5 (B). Solid black lines indicate the subjects with less severe pathology at baseline defined as CSF t-tau < 627 pg/ml (A) and mean MTA score < 1.5 (B). Abbreviations: CSF = cerebrospinal fluid, t-tau = total tau, MTA = medial temporal lobe atrophy, MMSE = mini-mental state examination.
DISCUSSION
Our main findings are that in subjects with MCI-AD, the injury markers CSF t-tau and p-tau, medial temporal lobe atrophy and MMSE score were associated with rapid progression to dementia. Age, gender, educational level, APOE status and CSF level of Aβ1-42 were not associated with time to dementia in subjects with MCI-AD. Among all subjects with MCI, risk factors age, gender and APOE status, the amyloid and injury markers of AD pathology and MMSE score were all associated with the diagnosis of MCI-AD, which is consistent with previous studies.
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Our results suggest that risk factors, amyloid markers and injury markers may have a different role in the diagnosis and prognosis of MCI-AD (table 4). Risk factors and CSF level of Aβ1-42 could predict whether a subject with MCI had MCI-AD. However, they were not associated with time to dementia in subjects with MCI-AD. This is in line with previous studies suggesting that amyloid-ß accumulation may reach a plateau early in the course of the disease and does not change much with disease progression. 6, 24, 25 This makes amyloid a useful marker for early diagnosis of AD, but not for determining further prognosis. The injury markers of AD pathology, on the contrary, were not only associated with MCI-AD in subjects with MCI, but were also associated with rapid decline to dementia in subjects with MCI-AD. This suggests that these markers could act as stage markers of AD-related neurodegeneration and could be used for prognosis. These findings are in line with the amyloid cascade hypothesis. 6, 8 The association of injury markers with time to AD-type dementia we found, could either be caused by a more aggressive course of the disease or indicate that subjects with more abnormal injury markers were already in a more advanced stage of the disease at baseline. The slope analyses suggest that subjects with increased tau were in a more advanced stage of the disease rather than that they had a more aggressive course, as baseline MMSE scores were different but not the slope of decline on the MMSE. In line with this, subjects with increased tau tended to have a longer duration of self-reported complaints at their first visit to our memory clinic Abbreviations: MCI = mild cognitive impairment, MCI-AD = subjects with mild cognitive impairment at baseline who progressed to AD-type dementia during follow up, CSF = cerebrospinal fluid, Aβ1-42 = amyloid-ß1-42, t-tau = total tau, p-tau = tau phosphorylated at threonine 181, MTA = medial temporal lobe atrophy, MMSE = minimental state examination.
(3.1±4.1 years vs 1.8±1.2 years, p=0.1). Previous studies in subjects with AD-type dementia on the contrary, found that high CSF levels of tau were associated with more rapid cognitive decline, 26, 27 suggesting that subjects with abnormal levels of CSF tau indeed suffer from a more aggressive disease course. A study in subjects with MCI-AD did not find a significant association between CSF t-tau and p-tau and time to dementia, 13 For medial temporal lobe atrophy, we found no significant difference in MMSE score at baseline between the 2 groups and there was no difference in self-reported disease duration at baseline (2.1±1.9 years vs 2.1±1.4 years, p=1.0). However, subjects with medial temporal lobe atrophy tended to show more rapid decline in MMSE score, indicating a more aggressive course. The association of atrophy with rate of decline may be related to reduced brain reserve capacity or a more aggressive subtype presenting with hippocampal atrophy. In a previous study, hippocampal atrophy also predicted time to AD-type dementia in subjects with MCI and abnormal amyloid-ß markers, 25 consistent with our own findings. The association between MMSE and time to dementia may be explained by the fact that subjects with a lower MMSE score are closer to the threshold of dementia. They had by definition a lower score at baseline, but did not show more rapid decline in MMSE score compared to subjects with high scores at baseline. In our multivariate model, medial temporal lobe atrophy was the strongest predictor for time to dementia and CSF t-tau tended to predict outcome. As the HR of MTA and CSF t-tau in this multivariate model was similar to that in the univariate model, it seems that these markers reflect independent pathophysiological processes, which is supported by the results of the MMSE slope analyses. Our selection of subjects with MCI that all progressed to AD-type dementia allowed us to identify markers specifically associated with time to dementia, rather than markers of risk for AD per se. This is important from a pathophysiological perspective, although this selection of subjects limits direct clinical applicability of the results. Strengths of our study are the large number of clinically well-characterized subjects with MCI and the fact that all subjects underwent standardized clinical procedures. Clinical follow up of the subjects was long, up to 7 years. A limitation was that the intervals between clinical visits were variable, since most follow up was part of regular patient care. Because we defined time to dementia using the date of the visit on which AD-type dementia was diagnosed, we may have overestimated the time to the onset of dementia. However, if we used as conversion date the date between the date of AD diagnosis and last visit before AD diagnosis, similar results were obtained (data not shown). We did not use the standard AD cut-offs for CSF markers, since most subjects had abnormal values of CSF markers according to those cut-offs. [13] [14] [15] As an alternative, we dichotomized scores using a split-half approach (table   2) , although these cut-offs have not yet been validated. While the Kaplan-Meier analyses were not corrected for age, gender and education, Cox regression with correction for age, gender and education showed essentially the same results. This is consistent with our observation that age, gender and educational level did not predict time to dementia in subjects with MCI-AD. Since we defined MCI-AD based on progression to AD-type dementia during follow up, we may have misclassified subjects with MCI-AD as stable MCI because of the limited follow-up period. In that case differences between subjects with MCI-AD and stable MCI may have been underestimated. Another limitation is that we did not have data of APOE genotype, CSF and MRI of all subjects.
Our results have important implications for research as well as for patient care. Now that it is possible to diagnose AD in subjects with MCI using biomarkers, 3, 4 it is increasingly important to identify prognostic markers, especially for the rate of progression to dementia. Our findings suggest that the diagnostic work-up of subjects with MCI may have a two-step approach. First, in the absence of other disorders associated with decreased CSF Aβ1-42 such as neuroinflammation and cerebrovascular changes, amyloid markers can be used to define whether prodromal AD is present. Second, injury markers could be used to determine prognosis. Whether injury markers can predict progression in individual subjects remains to be confirmed in independent prospective cohort studies.
